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non-small cell lung cancer: a meta-analysis
Woda Shi1, Wei Zhang2, Haoliang Sun2 and Yongfeng Shao2*Abstract
Aim: It is controversial that whether sleeve lobectomy (SL) should be promoted more worthy than
pneumonectomy (PN) in suitable patients.
Methods: We searched all studies that had been published in English from PUBMED and Embase which compared
the short-term and long-term outcomes of SL and pneumonectomy (PN) in patients with non-small cell lung
cancer (NSCLC).
Results: Nineteen studies met our criteria with a combined total of 3878 subjects, of which 1316 (33.9%)
underwent SL and 2562 (66.1%) underwent PN. The odds ratio was 0.50 (95% CI: 0.34-0.72) for postoperative
mortality, 1.17 (95% CI: 0.82-1.67) for postoperative complications, 0.78 (95% CI: 0.47-1.29) for locoregional
recurrences. The risk difference for 1-, 3-, 5- year was 0.11 (95% CI: 0.07-0.14), 0.15 (95% CI: 0.06-0.24), 0.15 (95% CI:
0.09-0.20),respectively. The pooled hazard ratio was 0.63 (95% CI: 0.56-0.71) in favor of SL group.
Conclusion: SL is more worthy to be done than PN in suitable patients with less mortality and better long-term
survival.
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Since sleeve lobectomy uasge in lung cancer was first
introduced by Sir Prince Thomas in 1947 [1], it has been
regarded as standard management for treatment of
patients with non-small cell lung cancer (NSCLC), who
have low-grade, centrally located lesions and whose pul-
monary reserve is insufficient and does allow pneumon-
ectomy. As patient-selection criteria have changed and
surgical techniques have been improved over the years,
sleeve lobectomy is also performed for such patients
who can tolerate pneumonectomy. Even when the
tumors involve not only the airway but also the central
vascular structures, in particular the pulmonary artery,
sleeve lobectomy is done concomitantly with pulmonary
artery reconstruction (double sleeve) in preference to
pneumonectomy. Several studies have shown that long-
term survival after sleeve lobectomy is similar to or even
better than that after penumonectomy with better pres-
ervation of lung function, and a better quality of life.* Correspondence: yongfeng_shao@163.com
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reproduction in any medium, provided the orHowever, it remains controversial whether sleeve lobec-
tomy is associated with a high rate of postoperative
complications and operative mortality. In the current
meta-analysis, we sought to assess whether sleeve lob-
ectomy concomitant with or without pulmonary artery
reconstruction or pneumonectomy offered a low mor-
bidity and mortality and a better long-term survival for
NSCLC patients.Methods
Search strategy and study selection
Relevant studies were identified and selected by search-
ing the databases-PubMed and Embase (updated to
October 2011), -using the search words ‘sleeve resection
or lobectomy and/or pneumonectomy’ and ‘lung neoplasm
and/or non-small cell lung cancer and/or NSCLC)’.
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images. Studies on sleeve lobectomy concomitant with
pulmonary artery reconstruction (double sleeve) were
also searched using the search words ‘pulmonary artery re-
construction or pulmonary artery sleeve resection or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bibliographies in relevant articles and conference pro-
ceedings. The following selection criteria were applied:
(1) non-small-cell lung cancer; (2) comparison of the
surgical results of sleeve lobectomy concomitant with
or without pulmonary artery reconstruction versus
pneumonectomy; (3) the trials should report on pul-
monary artery reconstruction associated with lobec-
tomy or bronchial sleeve resection; (4) the trials should
report at least one outcome; (5) a given patient popula-
tion was used only once; if the same population
appeared in other publications, the article that provided
the most complete follow-up data was selected; (6) we
excluded trials in which participants were subjected to
carinal or tracheal resection.
Data extraction
Data were independently extracted from each study
by two researchers (SYF, SWD). Any disagreement
was resolved by discussion and consensus opinion.
We extracted data on study characteristics, patient
clinical characteristics and demographics, histologic
type of tumor, distribution of stage, and duration of
follow-up. Primary outcomes included postoperative
mortality, postoperative complications; additional out-
comes included locoregional recurrences, difference of
survival of the two techniques at 1, 3, and 5 years, and
other adverse events.
Statistical methods
Meta-analysis was carried out using odds ratio (OR), risk
difference (RD), and hazard ratio (HR) as the primary ef-
fect measures. The effect measure OR was used to
analyze the odds of an adverse event occurring in the
sleeve lobectomy group compared to the pneumonec-
tomy group, while RD was used to analyze the difference
in survival of patients in the sleeve lobectomy and the
pneumonectomy groups. A fixed-effects or random-
effects model was employed [2].
For each meta-analysis result, Cochran’s Q and I2 sta-
tistics were first calculated to assess the heterogeneity
among the proportions of the included trials. If the P-
value was < 0.1, the assumption of homogeneity was
deemed invalid, and the random-effects model was
reported after exploring the causes of heterogeneity [3].
Otherwise, the fixed-effects model was reported. The cu-
mulative meta-analysis [4] over time was also used for
postoperative mortality and complications. If the OR
was less than 1, while the RD was more than 0, this
favored the sleeve lobectomy group, and the points of
estimate of the OR and RD were considered statistically
significant at the P < 0.05 level if the 95% confidence
interval did not include the value 1 or 0, respectively.
The log HR and its variance were used for the time-to-event analysis. In case the hazard ratio (HR) was not dir-
ectly given in the publication, we extracted summary
statistics from Kaplan-Meier product-limit estimations
and estimated HRs according to methods proposed by
Parmar in 1998 [5]. For estimation, we applied a tool,
which uses P-values of the appropriate log-rank test
comparing the two survival functions of interest, num-
ber of patients analyzed, and number of events in each
arm [6]. If this information was not available, HR was
deduced from the graphical display of the survival
curves, if possible. Survival data were pooled by the Der
Simonian and Laird method to produce a random-effect
meta-analysis. Heterogeneity between studies was inves-
tigated by the standard chi-squared Q-test.
The effect of publication and selection bias on the
summary estimates was tested by both the Harbord-
Egger bias indicator and Begg-Mazumdar bias indicator.
Also, a funnel plot was constructed to evaluate potential
publication bias by using the standard error of the log
OR and log OR. A two-tailed P-value < 0.05 was consid-
ered statistically significant. Calculation was conducted
using STATA version 11.0 (Stata Corporation, College




Our search yielded a total of 544 potentially relevant
clinical studies on sleeve lobectomy versus pneumonec-
tomy. After excluding review articles, observational stud-
ies, case reports, meta-analyses, a total of 19 trials [7-25]
with 3,878 subjects were included in this analysis; these,
1,316 patients (33.9%) had undergone sleeve lobectomy
and 2,562 (66.1%) pneumonectomy.
The characteristics of these studies are shown in
Table 1. The distribution of stages in the sleeve lobec-
tomy group and the pneumonectomy group was signifi-
cantly different (stages I, II, and III, 35.00%, 38.32%,
and 26.68% for sleeve lobectomy, and 19.72%, 32.32%,
and 47.96% for pneumonectomy; P < 0.001). Sex ratios
for the two groups showed no significant difference
(male/female, 82.16%/17.84% for sleeve lobectomy, and
80.00%/20.00% for pneumonectomy; P = 0.134). There
was no difference between the two groups in mean age
(62.88 years for sleeve lobectomy, 62.06 years for pneu-
monectomy; P = 0.4963), although age distributions were
not available.
Postoperative mortality
The meta-analysis showed that the pooled postoperative
mortality in patients undergoing sleeve lobectomy was
2.91% (38/1,306) as compared with 5.86% (149/2,542) in
patients receiving pneumonectomy, and there was a sig-
nificant difference in the postoperative mortality, which
Table 1 Study characteristics included in the meta-analysis
Authors Year Number Mean age Male/female Stage I Stage II ≥ Stage III
SL PN SL PN SL PN SL PN SL PN SL PN
Gaissert et al. 1996 72 56 63.4 60.8 56/16 42/14 29 9 31 25 12 22
Yoshino et al.a 1997 29 29 60.6 58.2 26/3 23/6 9 9 12 12 8 8
Suen et al.b 1999 58 142 63.7 66.5 41/17 81/61 18 37 28 46 12 59
Okada et al. 2000 60 60 60.9 60.6 52/8 53/7 / / / / / /
Ghiribelli et al. 2002 38 127 65 62.4 36/2 102/25 16 29 10 43 12 55
Martin et al. 2002 38 81 65 63 27/11 63/18 10 10 16 32 12 39
Deslauriers et al. 2004 184 1,046 60 60.7 152/32 827/219 82 164 72 361 30 521
Bagan et al. 2005 66 151 60.7 58.16 58/8 138/13 40 35 14 35 12 81
Kim et al. 2005 49 49 58.7 58.1 44/5 46/3 14 24 20 13 15 12
Lausberg et al. 2005 171 63 61.5 60.9 136/35 56/7 33 7 80 32 58 24
Ludwig et al. 2005 116 194 62 59 / / 31 32 41 52 44 110
Takeda et al. 2006 62 110 61.1 59.3 46/16 92/18 26 24 19 14 17 72
Balduyck et al. 2008 10 20 65.3 63.3 / / 2 3 1 9 7 8
Melloul et al. 2008 69 78 / / / / 15 28 30 21 24 29
Parissis et al. 2009 79 129 60.44 62.5 54/25 91/38 / / / / / /
Hanagiri et al.c 2010 24 72 65.1 64.7 18/6 61/11 5 5 8 13 11 54
Park et al. 2010 105 105 61.25 62.24 99/6 98/7 44 43 32 36 29 26
Bolukbas et al. 2011 31 29 73.6 74.2 25/6 25/4 5 2 17 10 9 17
Gomez-Caro et al. 2011 55 21 63.5 62.4 51/4 18/3 33 7 20 13 2 1
Total 1,316 2,562 62.89 62.06 921/200 1,816/454 412 468 451 767 314 1,138
aContaining two cases of small-cell carcinoma in the sleeve lobectomy (SL) group and one in the pneumonectomy (PN) group; bcontaining two cases of resection
of the tracheal carina in SL; ccontaining two cases of right upper sleeve lobectomy with carinoplasty in SL.
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0.34, 0.72), as shown in Figure 1. By plotting the emer-
gence of sleeve lobectomy with time (Figure 1), it was
clear that the earlier trials of sleeve lobectomy fitting our
inclusion criteria conducted before 2005 demonstrated a
high degree of heterogeneity. Since 2005, the overall ef-
fect size for postoperative mortality has remained rela-
tively stable within an effect size between OR of 0.49
and 0.60.Postoperative complications
Twelve studies [7,8,10,11,14,15,18,20,22-25] reported the
incidence of postoperative complications, and the meta-
analysis showed a pooled incidence of 32.88% (217/660)
with sleeve lobectomy, and 27.06% (240/887) with pneu-
monectomy (OR 1.17, 95% CI 0.82, 1.67), but this was
not statistically significant (Figure 2). The cumulative
meta-analysis also showed no statistical significance.Locoregional recurrences
Locoregional recurrences were reported in ten studies
[8,10,13-15,18,21,23-25] and resultant data from meta-
analysis showed the pooled locoregional recurrence in
sleeve lobectomy was 14.44% (104/720) compared with
26.08% (451/1,729) in pneumonectomy, but this was notstatistical significant (OR 0.78, 95% CI 0.47, 1.29), as
shown in Figure 2.
Survival at 1, 3, and 5 years and overall survival
Ten studies [8-11,13-18] were extracted for analysis of
the differences of survival at 1 year, which showed a
combined RD of 0.11 (95% CI 0.07, 0.14) in favor of the
sleeve lobecteomy group (Figure 3). Similar results were
achieved for differences in survival at 3 years (in six
studies [9,10,15,17,18,23], RD 0.15, 95% CI 0.06, 0.24)
and 5 years (in twelve studies [9-11,13-18,21-23], RD
0.15, 95% CI 0.09, 0.20). All the estimated combined
RD were statistically significant. In addition, 13 studies
[8-11,14-18,21,22,24,25] including 2,014 patients, 838 in
the sleeve lobectomy group and 1,176 in the pneumon-
ectomy group were extracted for meta-analysis of overall
survival. The summaries of individual studies and overall
pooled survival are shown in Figure 4. The estimated
combined HR for overall survival in 13 studies was 0.63
(95% CI 0.56, 0.71) in favor of the sleeve lobectomy
group, and there was a statistically significant difference.
Publication bias
Presence of publication bias analysed using the
Harbord-Egger bias indicator gave a value of -0.42 (95%
CI -1.51-, 1.01, P = 0.68), indicating that there was no
Figure 1 Conventional and cumulative meta-analysis of selected studies comparing postoperative mortality between the sleeve
lobectomy group and the pneumonectomy group.
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Figure 2 Meta-analysis of selected studies comparing postoperative complications and locoregional recurrences between the sleeve
lobectomy group and the pneumonectomy group.
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Figure 3 Meta-analysis of selected studies comparing differences in survival at 1, 3, and 5 years between the sleeve lobectomy group
and the pneumonectomy group.
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Figure 4 Meta-analysis of overall survival hazard ratios in individual studies and across all studies.
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Kendall tau b value of 0.11 (P = 0.91), suggesting no
publication bias. The funnel plots also show no publica-
tion bias (Figure 5).
Discussion and conclusion
Our study analyzed 19 clinical trials of sleeve lobectomy
versus pneumonectomy, including a total of 3,878 sub-
jects, of whom 1,316 (33.9%) underwent sleeve lobec-
tomy and 2,562 (66.1%) underwent pneumonectomy.
The sex ratios or mean ages for the two groups showed
there were no significant difference, but the distribution
of stages in the sleeve lobectomy group and pneumonec-
tomy groups was significantly different (stages I, II, and
III: 35.00%, 38.32%, and 26.68% for sleeve lobectomy;
19.72%, 32.32%, and 47.96% for pneumonectomy; P <
0.001; 17 reports), indicating that sleeve lobectomy is
promoted as more worthy for early stage NSCLC and
may has a better prognosis.
Patients receiving sleeve lobectomy showed significant
superior outcomes compared to those receiving pneu-
monectomy in terms of postoperative mortality, especiallyfor trials after 2005, indicating that sleeve lobectomy is
more likely to be performed with advances in surgical
technology and skills. In terms of postoperative compli-
cations and locoregional recurrences, no significant dif-
ference was found between patients receiving sleeve
lobectomy and those receiving pneumonectomy. Patients
who had undergone sleeve lobectomy showed a clear
advantage over those who received pneumonectomy in
terms of 1, 3, and 5-year survival and the time-to-event.
We also tried to carry out meta-analysis of differences in
long-term survival by different clinical stages or nodal
status between patients receiving sleeve lobectomy and
pneumonectomy, but we failed to obtain an adequate
number of eligible trials or sufficient clinical data.
Only five studies [7,13,17,18,21] compared the long-
term survival between groups by different clinical stages,
and six studies [10,11,13,15,17,21] by different nodal sta-
tus. Both Deslauriers et al [13] and Okada, et al. [10]
reported a better prognosis after sleeve lobectomy treat-
ment in patients with stages I and II diseases. Takeda,
et al. [18] did not report any difference in five-year sur-
vival for patients at stages I and II after sleeve lobectomy
Figure 5 Funnel plot evaluating the effect of publication bias on studies for postoperative mortality.
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the sleeve lobectomy group was better than in the pneu-
monectomy group (54% vs. 33%). Okada, et al. [10]
reported a significant difference among patients classifi-
cation of nodal disease (N) 0 or N1 in favor of sleeve
lobectomy, and Deslauriers, et al. [13] reported a signifi-
cant difference among patients with N0 disease in
favor sleeve lobectomy. Both Okada, et al. [10] and
Deslauriers, et al. [13] reported there was no significant
difference among patients with N2 disease. Additionally,
both Kim, et al. [15] and Parissis, et al. [21] reported
there was no significant difference among patients with
advanced nodal disease. Furthermore, Takeda, et al. [18]
reported that patients with stage III cancer in the pneu-
monectomy group, who received induction therapy, had
a marginally better survival rate compared to those in
the sleeve lobectomy group.
Few studies compared the lung function injury [7,12,24,25]
and quality of life [19,25] after the two operation proce-
dures, and the evaluation indexes varied, which made us
unable to perform a meta-analysis of these two outcomes.
Martin, et al. [12] and Gomez-Caro, et al. [25] reported
there was a significant difference in favor of those receiv-
ing sleeve lobectomy in mean perioperative loss of FEV1
(forced expiratory volume in one second) and FVC (forced
vital capacity). Melloul, et al. [20] reported that the post-
operative loss of FEV1 and DLCO (diffusing capacity for
carbon monoxide) were significantly higher after pneu-
monectomy than after sleeve lobectomy in patients <
70 years of age, and that the postoperative loss of FEV1,
but not DLCO (No statistical difference), was significantly
higher after pneumonectomy than after sleeve lobectomy
in patients > 70 years of age. Balduyck, et al. [19] reportedthere was a significant differences in physical functioning,
role functioning, cognitive functioning and shoulder dys-
function in favor of sleeve lobectomy.
The limitations of the present meta-analysis were as
follows: (1), some studies contained a few patients who
did not have NSCLC or tracheal carina resection, as illu-
strated in Table 1. (2) The disease stage distribution in
the sleeve lobectomy and pneumonectomy groups were
quite different, which might have led to unreliable
results and favored the sleeve lobectomy group. (3) The
definitions of postoperative mortality, postoperative
complications and locoregional recurrences were differ-
ent. (4) Preoperative neoadjuvant therapy, and post-
operative radiotherapy or chemotherapy may interfere
with the survival results. (5) Most of studies were retro-
spective because a randomized prospective trial is not
possible. (6) Publication bias might affect the meta-
analytic results, potentially producing overstated conclu-
sions. (7) The analysis of long-term results according to
different stages and nodal status were dropped due to an
insufficient number of studies and inadequate clinical
data. Finally, there were not enough studies comparing
the loss of lung function and quality of life after the two
operation procedures.
In conclusion, our study demonstrates that, (1) with
advances in patient selection criteria and surgical techni-
ques, sleeve lobectomy with or without pulmonary artery
reconstruction is effective and can be done safely with
lower mortality and without increasing morbidity and
locoregional recurrence, as compared to pneumonec-
tomy. (2) Sleeve lobectomy could offer better long-term
survival than pneumonectomy. (3) Patients receiving
sleeve lobectomy may have less loss of function and
Shi et al. World Journal of Surgical Oncology 2012, 10:265 Page 9 of 9
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tomy, but more evidence is required.
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